Review maps drugs that target the hallmarks of aging, from metformin to NAD+ precursors
A narrative review links aging hallmarks to metformin, rapamycin, senotherapeutics and NAD+ precursors, but says human evidence remains mixed.
Summary
This review looks at the biological processes that drive aging, often called the hallmarks of aging, and at the drugs being explored to slow them. The authors cover nutrient sensing, cellular senescence (cells that stop dividing and release harmful signals), and mitochondrial dysfunction (energy-producing parts of cells that work less well with age). Drugs discussed include metformin, rapamycin, senotherapeutics and NAD+ precursors. The authors say these agents show potential to improve healthspan and reduce disease burden. They also say the human evidence is heterogeneous, meaning results vary and do not point in one clear direction. Their conclusion is that targeting the hallmarks is a promising strategy, but well-designed clinical studies are still needed to establish efficacy, safety and benefits that matter to patients. This summary is based on the abstract only.
Detailed Summary
Why this matters: Aging is the biggest risk factor for most chronic diseases. The hallmarks of aging framework gives researchers a list of biological processes that could be targeted with drugs, rather than treating each age-related disease on its own. This review asks how far that idea has moved from mechanism toward medicine.
What was studied: The authors, from West China Hospital, Sichuan University, wrote a narrative review. It is not a systematic review or a meta-analysis. They summarize the main hallmarks of aging, how these connect to age-related diseases, and the pharmacological strategies aimed at them. The pathways covered include nutrient sensing, cellular senescence and mitochondrial dysfunction, among others.
Key results: The drug classes discussed are metformin, rapamycin, senotherapeutics and NAD+ precursors. The abstract reports that these agents show potential to improve healthspan and reduce disease burden. It also states that human evidence remains heterogeneous. The abstract gives no effect sizes, trial counts or head-to-head comparisons, and it does not say which results come from animals and which from people.
Implications: The review supports the view that the mechanisms behind aging can be targeted, and that these four drug classes are the leading candidates. The mechanistic rationale is worth following. It is not the same as proof that any of these drugs extends healthy life in people. The authors call for well-designed clinical studies to establish efficacy, safety and clinically meaningful benefit.
Caveats: This summary rests on the abstract alone because the full text is not open access. Details on dosing, safety, specific trials and the balance of animal versus human data could not be assessed. A narrative review also carries risks of selective citation. Readers should treat it as a map of the field, not as treatment guidance.
Key Findings
- Narrative review covers drugs aimed at nutrient sensing, cellular senescence, mitochondrial dysfunction and other aging pathways.
- Agents discussed: metformin, rapamycin, senotherapeutics and NAD+ precursors.
- Authors say these agents show potential to improve healthspan and reduce disease burden.
- Human evidence is described as heterogeneous; efficacy and safety still need well-designed clinical studies.
Methodology
This is a narrative synthesis of mechanistic and clinical evidence on candidate gerotherapeutics, not a systematic review or meta-analysis. The abstract does not describe search methods, study selection or quality appraisal.
Study Limitations
This summary is based on the abstract only, as the full text is not open access. The abstract gives no data on effect sizes, doses, harms, or the split between animal and human evidence. Narrative reviews can be subject to selective citation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
